miRagen Therapeutics

Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in certain diseases. The company has three product candidates, cobomarsen, remlarsen and MRG-110, in clinical development. Cobomarsen is an inhibitor of miR-155, which is a microRNA that is found at abnormally high levels in malignant cells of several blood cancers. Remlarsen is a replacement for miR-29, a microRNA that is found at abnormally low levels in a number of pathological fibrotic conditions. MRG-110 is an inhibitor of miR-92, a microRNA expressed in endothelial cells.
  • TickerMGEN
  • ISINUS60463E1038
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Promising New Preclinical Data for MRG-229 in IPF

1 director bought

A director at Miragen Therapeutics Inc bought 10,000 shares at 4.770USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Promising New Preclinical Data for MRG-229 in IPF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch